PEGS conference in Boston May 1-5

VAR2Pharmaceuticals will be present at PEGS conference in Boston May 1-5. To arrange a meeting please contact salanti@var2pharmaceuticals.com

Continue reading

The role of oncofetal CSA is published in a major article

The role of oncofetal CSA is published in a major article in ”Molecular Cancer Research” by the founders of VAR2Pharmaceuticals. The publication was choosen as the front cover of the monthly peer reviewed journal and describes that onco-fetal CSA plays a key role in metastasis formation and that tre......
Continue reading

VAR2Pharmaceuticals announces

VAR2Pharmaceuticals announces the finalization of the second investment round of 3.3M Euros. ”We are very pleased to have secured further funding for our exciting portfolie of pre-clinical development programs” says CEO Ali Salanti.

Continue reading

VAR2Pharmaceuticals receives a 7 million DKK grant

VAR2Pharmaceuticals receives a 7 million DKK grant from the Danish Innovation Foundation for ”Targeting cancer using a malaria derived protein drug conjugate”.

Continue reading

Hope for a general cure for cancer

Copenhagen, Denmark, October 13, 2015:   Targeting carbohydrates provides a new Danish biotech company, VAR2 Pharmaceuticals, with an effective weapon against cancer. Today VAR2 Pharmaceuticals announced the publication of breakthrough data in the renowned scientific journal Cancer C......
Continue reading